Novel Poly(L-lactide-co-ε-caprolactone) Matrices Obtained with the Use of Zr[Acac]₄ as Nontoxic Initiator for Long-Term Release of Immunosuppressive Drugs

Table 1

Characterization of poly(L-lactide-co-ε-caprolactone) matrices containing cyclosporine A or rapamycine (𝑀_𝑛: number-average molar mass; 𝐷: molar-mass dispersity; 𝑇_𝑔: glass transition temperature, 𝑇_𝑚: melting temperature; 𝑙_LL, 𝑙_Cap: the average length of lactidyl and caproyl blocks; 𝑅: randomization ratio; 𝐼/𝑀: initiator to monomer molar ratio).

Copolymer	𝑀𝑛 (Da)	D	𝑇𝑔^a; (°C)	𝑇𝑚^b; (°C)	Average length of blocks	R	Copolymerization conditions
							𝐼/𝑀	Temp.	Time
Less random; PLACL 75 : 25	60 300	2.1	32	158	𝑙LL=5.13; 𝑙Cap=1.71	0.68	1/800	110°C	72 h
More random; PLACL 75 : 25	63 450	2.5	31	—	𝑙LL=4.28; 𝑙Cap=1.58	0.75	1/1000	120°C	72 h
PLACL 92 : 8	105 100	2.2	57	170	—	—	1/1000	120°C	72 h

aObtained by DCS (second heating); ^bobtained by DSC (first heating).